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Background. Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer
patients. Predictive biomarkers of everolimus efficacy have been investigated in primary breast cancer tissue without finding
univocal results.The goal of this study was to investigate the mutational burden in the metastatic site of endocrine-resistant tumors
treated with everolimus plus exemestane. Patients and Methods.Mass Array Sequenom platform was used to analyse genetic status
of 18 cancer-related genes in 25 archival tumor specimens from metastatic lesions and available primary matched breast cancer
tissue of patients treated with everolimus and exemestane for advanced disease. An exploratory analysis of everolimus efficacy in
terms of progression free survival benefit and single gene mutation was carried out. Results. The overall detection rate of mutation
was 30% and 38% frommetastatic and primary breast cancer samples, respectively. AKT1E17K was the most frequent mutated gene.
No primary breast cancer and matched relapse maintained the same mutation profile. Considering molecular pathways, the most
of the genes belong to PI3K pathway (AKT1E17K, PI3KCAE545K, and KITG565R,S709F). In patients with detected mutations in breast
and/or recurrence tissue the median PFS was 5,6 months while in the subgroup of patients with no mutations the median PFS
was 7,5 months. Conclusions. The mutational status of breast cancer recurrence allows the identification of some genes potentially
correlating tumor response/resistance to everolimus. The most frequently mutated genes were involved in the PI3K/AKT/mTOR
pathway highlighting that the deregulation of this pathway in the relapse plays a crucial role in the mechanisms of everolimus
resistance/sensitivity.Owing to the small sample size and the retrospective nature of the study, these correlationsneed to be validated
in a large prospective study.
1. Introduction
Breast cancer (BC) is the most common malignant tumor
in women. More than 70% of BCs are hormone receptor
positive (HR+) and human epidermal growth factor receptor
2 negative (HER2-) and potentially benefit from endocrine
therapies [1]. However, approximately 25% of these tumors
fail to respond to hormonal treatment because of the novo
or acquired resistance [2]. In the last decade, new targeted
therapies have been investigated, with the aim of improv-
ing treatment efficacy in patients progressed on endocrine
therapy. The double-blinded randomized placebo control,
phase III BOLERO-2 study, demonstrated that everolimus
plus exemestane improved progression free survival (PFS)
compared with exemestane alone in HR+ HER2- advanced
BC that recurred or progressed during/after nonsteroidal
aromatase inhibitors [3].
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Actually, the main challenge is the identification of
biomarkers able to predict which patients can benefit from
the addiction of targeted agents (such as everolimus) to hor-
monal treatment. A large number of preclinical and clinical
studies tried to identify predictive biomarkers of everolimus
sensitivity in endocrine resistance population. Several pre-
clinical analyses have suggested how the presence ofmutation
in PI3KCA/AKT/mTOR (phosphatidylinositol 3-kinase/pro-
tein kinase B/mammalian target of rapamycin) pathway aswell
as PTEN (phosphatase and tensin homolog) gene loss detected
onprimaryBC tissue correlateswith everolimus benefit [4, 5].
However, the following clinical trials in BC patients did not
confirm the correlation between PI3KCA/PTEN status and
clinical response [6–8]. This discordance could be in part
justified by the different mutational status between primary
tumors and metastatic site. To the best of our knowledge,
there are no data regarding the gene mutation status in
metastatic tissue and tumor sensitivity to everolimus.
The main purpose of this study was to investigate the
mutational burden in the metastatic site of endocrine-
resistant patients treated with everolimus plus exemestane in
our Institution. We used a panel of 18 genes known to be
involved in the mechanism of endocrine and targeted treat-
ments resistance. Moreover, we analysed the gene mutation
status of the available matched primary tumors.
2. Materials and Methods
2.1. Patient Population and Samples. We retrospectively iden-
tified fifty patients with HR+ HER2- metastatic BC pro-
gressed on/after endocrine therapies and treated with
exemestane plus everolimus in routine clinical practice at the
Modena Cancer Centre. All these patients wrote an informed
consent to study enrolment. Clinical and pathological char-
acteristics were collected from informatic archives. PFS on
everolimus and exemestane was defined as the time elapsed
between treatment initiation and first documented progres-
sion disease/death. Thirty-one patients performed a biopsy of
the local or distant recurrence; twenty-five of these patients
had stored paraffin blocks of metastatic tissue suitable for
gene analysis. In nineteen cases, the matched primary BCwas
available too (Figure 1). Metastatic site biopsy was performed
before starting the combination treatment in all the patients.
2.2. Gene Analysis. Gene analysis was performed in Molec-
ular Biology Laboratory of Modena Pathology Depart-
ment. DNA was extracted from formalin-fixed and paraffin-
embedded (FFPE) metastatic and primary BC tissues. The
FFPE tissues were cut and stained with haematoxylin and
eosin and a pathologist selected sections containing more
than 30 % tumor cells. Genomic DNA was isolated from
unstained 10 𝜇m-sections using QIAamp DNA Mini kit
(QIAGEN). The DNA concentration in the samples was
quantified using a spectrophotometer TrineanXpose and they
were diluted to a final concentration of 20 ng/𝜇l. DNA
samples were analysed by OncoCarta v2.0 panel using Mass
Array Sequenom platform following the manufacturer’s pro-
tocols (http://agenabio.com). This panel is able to detect 152
Figure 1: Flowchart of the study population.
somatic mutations across 18 oncogenes and tumor suppres-
sors (AKT1, BRAF,CTNNB1, FBX4, FBXW7, FGFR2, FGFR3,
GNAQ, KIT, KRAS, MAP2K1, MAP2K2, NRAS, PDGFR𝛼,
PIK3CA, PTPN11, SOS1, and TP53). The panel consists of
12 multiplexed wells that are run on each sample using 40
ng of input DNA from FFPE tissue. The polymerase chain
reaction amplification and primer extension were performed
using the OncoCarta Panel v2.0 reagents. The detection and
quantify mutation frequencies are ≥ 10%. Twenty patients
had successful DNA extraction from themetastatic site useful
for gene analysis. In thirteen cases, we had successful DNA
extraction from the matched primary BCs too.
3. Results
3.1. Study Population. Twenty-five patients have been en-
rolled in the study. Four patients were diagnosed with de
novo metastatic BC, while all the other cases relapsed in
spite of adjuvant treatments. All the patients progressed
on/after aromatase inhibitors and received at least two pre-
vious lines of (chemo- or hormonal-) therapies for advanced
disease. The median age at the time to start everolimus plus
exemestane was 54 years (range 50-67). Regarding the tumor
burden at the beginning of everolimus and exemestane, four
patients had only bone disease and two patients only loco-
regional recurrence (chest wall and/or lymph nodes), while
all other patients presented visceral disease (liver and/or
lung). Tumors characteristics of both metastatic site and
primary BC are reported in Table 1. According to 13th St
Gallen International Breast Cancer Conference classification,
seventeen patients relapsed as luminal B-like disease (HR+,
HER2-, Mib1 ≥ 20%), and eight were luminal A-like BCs
(HR+,Mib1 <20%). Primary BCwas luminal B-like in twelve
patients, whereas luminal A-like in the other ones. Of note,
in two patients the BC subtypes changed from luminal A-
like to luminal B-like from primary breast disease to relapse,
whereas in other two cases it changed from luminal B-like to
luminal A-like from breast sample to metastasis. At the time
of analysis, all the patients had progressed on everolimus and
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Table 1: Tumors characteristics of metastatic site and matched primary breast cancer.
Relapse Primary tumor
Site of biopsy relapse characteristics Primary tumor characteristics
Patient 1 liver CDI ER90%, PgR 5%, Mib1 30%, HER2 1+ CDI ER100%, PgR60%, MIb1 25%, HER2 1+
Patient 2 breast CDI ER60%, PgR 95%, Mib1 10%, HER2 1+ CDI ER98%, PgR98%, MIb1 15%, HER2 1+
Patient 3 liver CDI ER40%, PgR30%, Mib1 40%, HER2 0 CDI ER98%, PgR70%, MIb1 30%, HER2 1+
Patient 4 liver CDI ER100%, PgR 50%, Mib1 40%, HER2 1+ CDI ER100%, PgR80%, MIb1 25%, HER2 1+
Patient 5 chest wall CDI ER 99%, PgR70%, Mib1 15%, HER2 0+ CDI ER 99%, PgR 70%, MIB1 15%, HER2 1+
Patient 6 liver CDI ER 95%, PgR2%, Mib1 25%, HER2 1+ CDI ER 85%, PgR 70%, MIB1 35%, HER2 1+
Patient 7 lung CDI ER 85%, PgR25%, Mib1 15%, HER2 1+ CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 8 breast CDI ER 100%, PgR100%, Mib1 30%, HER2 1+ CDI ER 100%, PgR 100%, MIB1 35%, HER2 1+
Patient 9 liver CDI ER 99%, PgR99%, Mib1 50%, HER2 1+ CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 10 liver CDI ER 90%, PgR60%, Mib1 22%, HER2 1+ CDI ER 50%, PgR 50%, Mib1 10%, HER2 1+
Patient 11 liver CDI ER 80%, PgR0%, Mib1 40%, HER2 1+ CDI ER 90%, PgR 50%, MIB1 25%, HER2 1+
Patient 12 skin CDI ER 99%, PgR50%, Mib1 25%, HER2 1+ not applicable
Patient 13 bone CDI ER 70%, PgR0%, Mib1 35%, HER2 0+ CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 14 bone CDI ER 50%, PgR5%, Mib1 25%, HER2 0+ not applicable
Patient 15 liver CDI ER 100%, PgR10%, Mib1 20%, HER2 1+ not applicable
Patient 16 lymph node CDI ER 70%, PgR0%, Mib1 25%, HER2 1+ CDI ER 90%, PgR 80%, MIB1 8%, HER2 0+
Patient 17 liver CDI ER 95%, PgR80%, Mib1 15%, HER2 0+ CDI ER 100%, PgR 100%, MIB1 15%, HER2 0+
Patient 18 lung CDI ER 90%, PgR2%, Mib1 30%, HER2 1+ CDI ER 50%, PgR 65%, MIB1 25%, HER2 0+
Patient 19 lung CDI ER 95%, PgR25%, Mib1 10%, HER2 1+ CDI ER 60%, PgR 10%, MIB1 25%, HER2 1+
Patient 20 lung CDI ER 75%, PgR50%, Mib1 10%, HER2 1+ CDI ER 75%, PgR 20%, MIB1 15%, HER2 0+
Patient 21 bone CDI ER 95%, PgR65%, Mib1 25%, HER2 1+ not applicable
Patient 22 bone CDI ER 95%, PgR95%, Mib1 10%, HER2 1+ CDI ER 100%, PgR 85%, MIB1 3%, HER2 0+
Patient 23 liver CDI ER 90%, PgR25%, Mib1 40%, HER2 0+ not applicable
Patient 24 lung CDI ER 50%, PgR50%, Mib1 30%, HER2 1+ CDI ER 70%, PgR 50%, MIB1 25%, HER2 1+
Patient 25 lymph node CDI ER 100%, PgR5%, Mib1 15%, HER2 0+ not applicable
exemestane. Median PFS was 6,6 months (range from 1 to 17
months).
3.2. Gene Mutations on Metastatic Site. Among twenty-five
patients enrolled, twenty had successfulDNAextraction from
FFPE metastatic site. In six of these patients, the biopsy
was performed on the local/regional recurrence site (breast,
chest wall, or lymph nodes). In nine cases, the biopsy was
performed on liver recurrence, in three patients on lung
metastasis, and in two cases on the spinal bone lesions.
In all but one case the mutations were detected in the
visceral recurrence (liver or lung) (Figure 2). Gene mutations
were identified in 6 out of 20 patients analysed (30%). All
but one of them had only onemutated gene (BRAF, CTNNB1,
FBXW7, KIT, or PT53). Only patient 6 presented two
mutations: one on PI3KCA and one on AKT1, respectively
(Table 2). Considering molecular pathways, the most of the
detected genes belong to PI3Kpathway (AKT1, KIT, PI3KCA,
and PT53), APC pathway (CTNNB1, FBXW7, and PT53), and
MAP and RAS pathways (AKT1 and KIT; AKT1 and BRAF,
respectively).
3.3. Gene Mutations on Primary Breast Cancer. Primary BC
tissue was available in nineteen patients but only in thirteen
cases the DNA was successfully extracted. The overall detec-
tion rate of mutations in the primary BC was 38% (5 out of
13 patients). A single gene mutation was identified in four
out of thirteen patients analysed. Only patient 7 presented
three mutations in three different genes: FBX4, PI3KCA, and
KIT. Two patients presented the same mutation on AKT1:
E17K.Other two cases had a single mutation onMAP2K1 and
FBXW7, respectively. Considering molecular pathways, the
most of the mutated genes belong to PI3K pathway (AKT1,
KIT, and PI3KCA), APC pathway (FBXW7and FBX4), and
MAPandRASpathways (AKT1 andMAP2K1; AKT1 andKIT,
respectively) (Table 2).
3.4. Correlation between Gene Mutations on Metastatic and
Primary Breast Cancer. The metastatic and the matched
primary BC tissues were profiled in eight patients; in three
of them no mutation has been detected in both samples. No
primary BC andmatched relapse maintained the same muta-
tion profile. Two patients acquired AKT1E17Kmutation in the
metastatic sites, while two patients lost the mutation detected
in the primary tissue. In patient 18 a single mutation on a
different gene was detected in primary tissue (FBXW7R479Q)
and in the recurrence one (MAP2K1D67N) (Table 2).
Overall AKT1 was the most frequent mutated gene, with
the same mutation E17K (one in the metastatic tissue and
two in the relapse ones). Similarly, the E545K was the only
mutation detected in PI3K gene. Mutations in KIT, PI3KCA,
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Figure 2: Oncogene mutations across metastatic and primary breast cancer site.
Table 2: Mutations detected in relapse tissue and in primary breast cancer.
Relapsemutations Primary tumor mutations
status gene mutation status gene mutation
Patient 1 wild type not available
Patient 2 mutated BRAF R444W not available
Patient 3 wild type not available
Patient 4 wild type not available
Patient 5 wild type not available
Patient 6 mutated PIK3CAAKT1 E545K E17K not available
Patient 7 not available mutated FBX4 PIK3CA KIT G30N E545K S709F
Patient 8 wild type not available
Patient 9 mutated TP53 R273H wild type
Patient 10 wild type mutated AKT1 E17K
Patient 11 wild type wild type
Patient 12 wild type not available
Patient 13 wild type mutated AKT1 E17K
Patient 14 wild type not available
Patient 15 mutated KIT G565R not available
Patient 16 wild type wild type
Patient 17 not available wild type
Patient 18 mutated FBXW7 R479Q mutated MAP2K1 D67N
Patient 19 wild type wild type
Patient 20 mutated CTNNB1 S45F wild type
Patient 21 not available wild type
Patient 22 not available mutated FBXW7 R465C
Patient 23 wild type not available
Patient 24 not available wild type
Patient 25 wild type not available
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Table 3: Correlation between mutations detected in primary tumor or relapse tissue and PFS on everolimus and exemestane.
Mutations in primary tumor or relapse tissue PFS (months)
Patient 1 wild type 3
Patient 2 mutated (BRAF) 6
Patient 3 wild type 4
Patient 4 wild type 5
Patient 5 wild type 2
Patient 6 mutated (PIK3CA; AKT1) 15
Patient 7 mutated (FBX4; PIK3CA; KIT) 3
Patient 8 wild type 17
Patient 9 mutated (TP53) 1
Patient 10 mutated (AKT1) 3
Patient 11 wild type 5
Patient 12 wild type 9
Patient 13 mutated (AKT1) 2
Patient 14 wild type 9
Patient 15 mutated (KIT) 3
Patient 16 wild type 8
Patient 17 wild type 13
Patient 18 mutated (MAP2K1; FBXW7) 6
Patient 19 wild type 5
Patient 20 mutated (CTNNB1) 8
Patient 21 wild type 12
Patient 22 mutated (FBXW7) 5
Patient 23 wild type 5
Patient 24 wild type 13
Patient 25 wild type 2
and FBXW7 were detected in both primary BC and relapse.
Regarding molecular pathways, the most of the genes belong
to PI3K, MAP, and APC pathways, with four mutated genes
involved in each pathway.
In patients with detected mutations in breast and/or
recurrence tissue, the median PFS was 5,6 months (range
from 1 to 15 months), while in the subgroup of patients with
no mutations the median PFS was 7,5 months (range from 2
to 17 months) (Table 3).
4. Discussion
Everolimus is a selective inhibitor of mTOR, a multipro-
tein complex controlled by mitogenic positive signal (medi-
ated through PI3K/AKT pathway) and by negative regulators
(such as PTEN) [9]. Receptors tyrosine kinase signalling and/
or acquired mutation in genes involved in PI3K/AKT path-
way can activate constitutively this complex [9, 10]. Hor-
mone resistance models have shown that tumors can loss
endocrine responsiveness through activation of PI3K/AKT/
mTOR [11]. The combination of mTOR inhibitors such as
everolimus and endocrine therapy can restore hormone sen-
sitivity to previously resistant tumors cells [12]. Everolimus
has been mainly investigated in combination with tamoxifen
in TAMRAD trial and with exemestane in BOLERO2 trial [3,
13]. The combination significantly reduced the risk of disease
progression and improved the clinical benefit rate compared
with endocrine therapy alone in metastatic BC patients resis-
tant to aromatase inhibitors. Translational studies of these
two trials tried to find biomarkers able to predict a patient’s
positive response or resistance to everolimus [6, 7]. In spite of
preclinical evidence showing a predictive role of specific
genetic aberrations in the PI3K/AKT/mTOR pathway [14,
15], clinical data failed to confirm the correlation between a
specific mutation status in the primary BC tissue and sensiti-
vity/resistance to everolimus.
On these premises, we analysed a panel of 18 genes known
to be involved in endocrine and targeted treatment resistance
in metastatic BC samples. Our study is the only one that
performed the gene analysis in metastatic tissue of endocrine
resistance BC patients before starting everolimus. That is
extremely important considering that during the natural his-
tory of the disease, metastases can acquire different biological
profiles as compared to their matched primary tumor [16, 17].
In our analysis, the overall detection rate of mutations
was 30%. Most of detected genes belong to PI3K pathway,
supporting this pathway as a key-point in endocrine resis-
tance BCs.Themutated genes in PI3Kpathwaywere PI3KCA,
AKT1, KIT, and PT53. All these genes are known to be
involved in BC progression and metastatization [18]. Several
preclinical studies have shown how PI3KCA and AKT1
mutations were able to activate PI3Kpathway and to be driver
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of BC progression. In particular, PI3KCA is mutated and/or
amplified in ∼30% of BCs [19]. In the TAMRAD study 45 pri-
mary tumor samples of BC were screening for mutation sta-
tus. No relationship between PI3Kmutations and everolimus
efficacy was found. The overall detection rate of mutations
was 22%. Nine patients (5 in tamoxifen/everolimus arm and
4 in tamoxifen alone arm) had a PI3K mutation: two in the
exons 9 (mutation E542K) and seven in exon 20 (mutation
H1047R) [7]. Furthermore, the BOLERO-2 study failed to
identify any specific gene mutation associated with a greater
benefit from everolimus, in both tumor tissue and plasma
cell-free DNA. Gene analyses were performed on 302 FFPE
archival tumor tissue. The genes most frequently mutated
were PI3KCA (47.6%), CCND1 (31.3%), TP53 (23.3%), and
FGFR1 (18.1%). None of these genes such as the pathways
alteration of which they were components predicted the PFS
benefit with everolimus. However, quantitative differences in
everolimus benefit were observed between patients subgroup
defined by the exon specific mutation in PI3KCA genes. In
particular, patients with the PI3KCA exon 9 (helical domain)
mutation had greater PFS benefit compared with those with
exon 20 (kinase domain) mutation [6]. The relationship be-
tween the PIK3CA exon 9 status and the efficacy of evero-
limus was investigated and confirmed in the subgroup anal-
ysis of the Phase II study of neoadjuvant everolimus plus
letrozole inHR+BC [20]. Interestingly, in our analysis patient
6 with both PI3KCAE545K (exon 9) and AKT1E17K mutation
experienced the greatest benefit from everolimus treatment
with a PSF of 15 months.
Notably, the activating mutations in AKT gene are
reported in 1.4%–8% of BCs, exclusively in HR+ tumors [21].
AKT1E17K is the most commonly reported mutation. This
mutation increases gene activity by promoting constitutive
localization of AKT1 to the plasmatic membrane [22]. In vitro
studies have shown how high levels of pAKT were predictor
of sensitivity to everolimus [21]. In our series, patient 10 and
patient 13 with AKT1E17K mutation only in the primary BC
had an extremely poor PFS on everolimus (5 and 2 months,
respectively).
Regarding TP53, another gene involved PI3K pathway,
in vitro evidence has shown how R273H mutation enhanced
proliferation, invasion, and drug resistance [23]. RNA anal-
ysis confirmed how TP53R273H mutants had the apoptosis
pathway less active than TP53 wild type ones [23]. In accor-
dance with this finding, Patient9 whit TP53R273H mutation
detected in the metastatic liver biopsy rapidly progressed on
the combination treatment (PFS = 1 month).
Less evidence is available regarding the predictive role
of the other mutated genes. In our series, poor PFS were
achieved by patient 2 with BRAFR444W, patient 15 with
KITG565R, and patient 18 with FBXW7R479Q mutation (6, 3,
and 5 months, respectively). These findings are consistent
with available data in literature deriving from preclinical
evidence but not specifically on BC [24–26]. Globally, median
PFS in our population was higher in wild type patients
compared with mutated ones. This finding is in accordance
with the conclusions of the BOLERO2 investigators where
patients with no alteration or a single genetic alteration re-
ceived a greater PFS benefit from everolimus.
Considering the correlation between gene mutation sta-
tus in the metastatic and matched BC tissue, no patient
maintained the same mutation profile. In contrast with
our evidence are the data from the mutational analysis
performed in the metastatic tissue of 56 patients enrolled in
the BOLERO2. In this subgroup analysis, the genetic profile
of metastatic and primary tumors was generally similar, with
a statistically increased mutation rates for ESR1, MDM2, and
DNMT3A in the metastatic samples [6]. This discordance
could be justified by the fact that our population was highly
pretreated. In fact, it should be noted that all our patients
received at least two lines of treatment for metastatic disease
before starting everolimus and more than 80% of them were
treated with chemotherapy for advance disease compared
to 26% in BOLERO2 study. The discordance between the
mutational profile of metastatic and primary BC tissue
further stresses the importance of the biopsy of the metastatic
site in order to catch important molecular markers that can
evolve during the disease progression. Finally, the high rate of
mutations detected in the primaryBCs tissue (5 of 13 analysed
patients, 38%) could highlight a more aggressive behaviour
of these tumors and the subsequent relapse in spite of the
adjuvant treatments.
Nevertheless, our study presents three major limitations.
The first is the small sample size due to preanalytic bias
in DNA extraction. Furthermore, a possible sampling bias
must be taken into account due to the heterogeneity of the
metastatic disease, where different areas of the same lesion
may show different genomic profiles [27, 28]. Finally, our
study focused on gene mutations, but the recent evidence
underline how microRNA expression, protein expression,
and abnormalities in DNAmethylation may influence the re-
sponse/resistance to antitumor treatments, independently
from genes profile [29, 30].
5. Conclusion
The mutational status of BC recurrence allows the iden-
tification of some genes potentially correlating to tumor
response/resistance to everolimus plus exemestane. Themost
frequently mutated genes among those investigated were
involved in the PI3K/AKT/mTOR pathway. It is likely that
the deregulation of this pathway in the relapse plays a crucial
role in the mechanisms of everolimus resistance/sensitivity.
Owing to the small sample size and the retrospective nature of
the study, these correlations are purely exploratory and need
to be validated in large prospective studies. Future research
should be directed not only on the analysis of genes profile
but also on the RNA expression, proteins level, and epigenetic
alteration.
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